Arrowhead (NASDAQ: ARWR)
("Arrowhead") President and Chief Executive Officer Dr. Christopher
Anzalone will be in attendance at the 21st Annual Roth Capital Partners OC Growth
Stock Conference in Dana Point, California on Tuesday, February 17, 2009 and
will be available to meet with members of the investment community. Arrowhead
is a nanotechnology company that is commercializing new technologies in the
areas of life sciences, electronics, and energy. As owners of key nanotechnology
assets in these markets, Arrowhead and its subsidiaries are well-positioned
to capitalize on a significant market opportunity. Key partners and customers
include Samsung Electronics, Tokyo Electron, Entegris, Inc. and The Battelle
To arrange a meeting with Dr. Anzalone at the Growth Stock Conference, please
contact: Virginia Dadey; Vice President, Investor Relations Telephone: 212.541.3707
Email: [email protected]
Arrowhead is building value for shareholders through the progress of majority
owned subsidiaries founded on nanotechnologies originally developed at universities.
The Company works closely with universities to source early stage deals and
to generate rights to intellectual property covering promising new nanotechnologies.
Arrowhead currently has two wholly owned subsidiaries (the "Subsidiaries"),
two majority-owned subsidiaries and has minority investments in two development
stage nanotechnology companies. The Company's Subsidiaries seek to commercialize
a variety of nanotech products and applications, including anti-cancer drugs,
RNAi therapeutics, carbon-based electronics and fullerene antioxidants. The
Company's minority investments are focused on developing advanced nanomaterials
for spinal cord injury and wound healing and drug delivery technology.